NEW YORK (360Dx) — Sienna Cancer Diagnostics said today that it has signed an agreement to evaluate its cancer hTERT in vitro diagnostic in thyroid cancer in collaboration with the Royal Melbourne Hospital (RMH) in Australia.

The test detects the hTERT component of telomerase, a biomarker that the company said is upregulated in about 85 percent of tissue-based cancers. Sienna currently markets the test as an aid in bladder cancer diagnosis alongside standard urine cytology testing.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.